xenograft model antitumor assays

Summary

Summary: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Top Publications

  1. ncbi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
  2. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
  3. pmc Guidelines for the welfare and use of animals in cancer research
    P Workman
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:1555-77. 2010
  4. ncbi Identification and expansion of the tumorigenic lung cancer stem cell population
    A Eramo
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Cell Death Differ 15:504-14. 2008
  5. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
  6. ncbi Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
    Akira Orimo
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 121:335-48. 2005
  7. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009
  8. pmc Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission
    Heather A Hirsch
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02115, USA
    Cancer Res 69:7507-11. 2009
  9. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
  10. ncbi Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4
    Matilde Todaro
    Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, 90127 Palermo, Italy
    Cell Stem Cell 1:389-402. 2007

Detail Information

Publications333 found, 100 shown here

  1. ncbi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
    ..In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha...
  2. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  3. pmc Guidelines for the welfare and use of animals in cancer research
    P Workman
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 102:1555-77. 2010
    ....
  4. ncbi Identification and expansion of the tumorigenic lung cancer stem cell population
    A Eramo
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Cell Death Differ 15:504-14. 2008
    ..Molecular and functional characterization of such a tumorigenic population may provide valuable information to be exploited in the clinical setting...
  5. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  6. ncbi Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
    Akira Orimo
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 121:335-48. 2005
    ..Our findings indicate that fibroblasts within invasive breast carcinomas contribute to tumor promotion in large part through the secretion of SDF-1...
  7. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009
    ....
  8. pmc Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission
    Heather A Hirsch
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02115, USA
    Cancer Res 69:7507-11. 2009
    ....
  9. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  10. ncbi Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4
    Matilde Todaro
    Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, 90127 Palermo, Italy
    Cell Stem Cell 1:389-402. 2007
    ..Our data suggest that colon tumor growth is dictated by stem-like cells that are treatment resistant due to the autocrine production of IL-4...
  11. ncbi RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    Georgia Hatzivassiliou
    Genentech, South San Francisco, California 94080, USA
    Nature 464:431-5. 2010
    ..Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors...
  12. ncbi Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    Sauveur Michel Maira
    Oncology Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH4002 Basel, Switzerland
    Mol Cancer Ther 7:1851-63. 2008
    ..Collectively, the preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties. NVP-BEZ235 is currently in phase I clinical trials...
  13. pmc Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
    Olivier Keunen
    Norlux Neuro Oncology Laboratory, Oncology Department, Centre de Recherche Public de la Santé, 1526 Luxembourg, Luxembourg
    Proc Natl Acad Sci U S A 108:3749-54. 2011
    ..The present work underlines the need to combine anti-angiogenic treatment in GBMs with drugs targeting specific signaling or metabolic pathways linked to the glycolytic phenotype...
  14. ncbi Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors
    Matus Studeny
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:3603-8. 2002
    ..Our results indicate that MSCs may serve as a platform for delivery of biological agents in tumors...
  15. ncbi Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas
    Akira Nakamizo
    Department of Neurosurgery, Brain Tumor Center, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 65:3307-18. 2005
    ....
  16. pmc Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Oncotarget 3:395-8. 2012
    ....
  17. pmc BRAF mutation predicts sensitivity to MEK inhibition
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nature 439:358-62. 2006
    ..These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype...
  18. pmc Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
    Alexa B Turke
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Cancer Cell 17:77-88. 2010
    ..These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy...
  19. pmc Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology Girona, ICO Girona
    Oncotarget 3:1600-14. 2012
    ..The degree of predictive accuracy warrants further investigation in the clinical situation...
  20. pmc Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types
    Dimitrios Iliopoulos
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
    Cancer Res 71:3196-201. 2011
    ....
  21. ncbi In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
    Klaus P Hoeflich
    Translational Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 15:4649-64. 2009
    ..We investigated the role of mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) inhibitors as targeted therapies for basal-like breast cancer...
  22. pmc Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
    Michael Degtyarev
    Genentech, Inc, South San Francisco, CA 94080, USA
    J Cell Biol 183:101-16. 2008
    ....
  23. pmc AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
    Sarat Chandarlapaty
    Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 19:58-71. 2011
    ..Consistent with this model, we find that, in tumors in which AKT suppresses HER3 expression, combined inhibition of AKT and HER kinase activity is more effective than either alone...
  24. pmc EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    Ryan B Corcoran
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Cancer Discov 2:227-35. 2012
    ..These findings support evaluation of combined RAF and EGFR inhibition in BRAF mutant CRC patients...
  25. ncbi Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth
    Guilherme Z Rocha
    Departments of Internal Medicine and Clinical Pathology, FCM, Universidade Estadual de Campinas UNICAMP, Campinas, SP, Brazil
    Clin Cancer Res 17:3993-4005. 2011
    ..Chemotherapy produces genotoxic stress and induces p53 activity, which can cross-talk with AMPK/mTOR pathway. Herein, we investigate whether the combination of metformin and paclitaxel has an effect in cancer cell lines...
  26. ncbi Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice
    Huanjie Yang
    The Prevention Program, Barbara Ann Karmanos Cancer Institute, and Department of Pathology, School of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Cancer Res 66:4758-65. 2006
    ..Our results show that Celastrol is a natural proteasome inhibitor that has a great potential for cancer prevention and treatment...
  27. ncbi CD133 expression defines a tumor initiating cell population in primary human ovarian cancer
    Michael D Curley
    Vincent Center for Reproductive Biology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Stem Cells 27:2875-83. 2009
    ..Our data indicate that CD133 expression defines a NOD/SCID tumor initiating subpopulation of cells in human ovarian cancer that may be an important target for new chemotherapeutic strategies aimed at eliminating ovarian cancer...
  28. pmc Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
    John F de Groot
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 12:233-42. 2010
    ..This model mimicked many of the histopathologic findings from the human cases and will augment the discovery of alternative or additive therapies to prevent this type of tumor recurrence in clinical practice...
  29. ncbi ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
    Cherrie K Donawho
    Abbott Laboratories, Abbott Park, Illinois 60064 6074, USA
    Clin Cancer Res 13:2728-37. 2007
    ..To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888...
  30. ncbi AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
    Stephen R Wedge
    Cancer Bioscience, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom
    Cancer Res 65:4389-400. 2005
    ..AZD2171 is being developed clinically as a once-daily oral therapy for the treatment of cancer...
  31. pmc Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies
    Guy Lahat
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 5:e10105. 2010
    ..Withaferin-A, a naturally derived bioactive compound, may molecularly target vimentin, so we sought to evaluate its effects on tumor growth in vitro and in vivo thereby elucidating the role of vimentin in drug-induced responses...
  32. pmc Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
    Dan Huang
    Laboratory of Cancer Genetics, Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Cancer Res 70:1063-71. 2010
    ..Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy...
  33. pmc Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    Gideon Bollag
    Plexxikon Inc, 91 Bolivar Drive, Berkeley, California 94710, USA
    Nature 467:596-9. 2010
    ..These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity...
  34. pmc The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
    ....
  35. ncbi Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
    ..Testing in other radiosensitive cancers is warranted...
  36. ncbi Mediating tumor targeting efficiency of nanoparticles through design
    Steven D Perrault
    Institute of Biomaterials and Biomedical Engineering, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, ON, M5S 3E1, Canada
    Nano Lett 9:1909-15. 2009
    ..Our results provide design parameters for engineering nanoparticles for optimized tumor targeting of contrast agents and therapeutics...
  37. ncbi Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays
    Mark G Manfredi
    Millennium Pharmaceuticals, Inc, Cambridge, 40 Landsdowne Street, Cambridge, MA 02139, USA
    Clin Cancer Res 17:7614-24. 2011
    ..Here, we describe preclinical characterization of alisertib (MLN8237), a selective AAK inhibitor, incorporating these novel pharmacodynamic assays...
  38. ncbi Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
    Charlotte F McDonagh
    Merrimack Pharmaceuticals, One Kendall Square, Cambridge, MA 02139, USA
    Mol Cancer Ther 11:582-93. 2012
    ..MM-111 can be rationally combined with trastuzumab or lapatinib for increased antitumor activity and may in the future complement existing ErbB2-directed therapies to treat resistant tumors or deter relapse...
  39. ncbi ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
    Alan E Wakeling
    Department of Cancer and Infection Research, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:5749-54. 2002
    ..These studies indicate the potential utility of ZD1839 in the treatment of many human tumors and indicate that continuous once-a-day p.o. dosing might be a suitable therapeutic regimen...
  40. pmc Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy
    Noriaki Sunaga
    Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
    Mol Cancer Ther 10:336-46. 2011
    ..Our findings suggest that targeting oncogenic KRAS by itself will not be sufficient treatment, but may offer possibilities of combining anti-KRAS strategies with other targeted drugs...
  41. ncbi Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
    Svetlana Komarova
    Division of Human Gene Therapy, Department of Medicine, Gene Therapy Center, University of Alabama at Birmingham, 901 19th Street South, BMR2 572, Birmingham, AL 35294 3300, USA
    Mol Cancer Ther 5:755-66. 2006
    ..These data show that MPCs can serve as intermediate carriers for replicative adenoviruses and suggest that the natural homing properties of specific cell types can be used for targeted delivery of these virions...
  42. pmc Novel therapies for metastatic castrate-resistant prostate cancer
    Farshid Dayyani
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Cancer Inst 103:1665-75. 2011
    ..The rationale to disrupt this "two-compartment" crosstalk has led to the development of drugs that target tumor stromal elements in addition to the cancer epithelial cell...
  43. pmc Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
    Sudhakar Chintharlapalli
    Department of Veterinary Physiology and Pharmacology, Texas A and M University, College Station, TX 77843, USA
    BMC Cancer 11:371. 2011
    ....
  44. ncbi YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Cancer Res 67:8014-21. 2007
    ..Further extensive investigation of YM155 in many types of cancer, including HRPC, seems to be worthwhile to develop this novel therapeutic approach...
  45. ncbi Cancer and the chemokine network
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Cancer 4:540-50. 2004
  46. ncbi Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1
    Ramzi M Mohammad
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    Clin Cancer Res 13:2226-35. 2007
    ..We have previously employed the natural product (-)-gossypol to test its therapeutic potential as a small-molecule inhibitor of Bcl-2 for the treatment of B-cell lymphomas...
  47. pmc Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
    Laura Bonapace
    Department of Oncology, University Children s Hospital, University of Zurich, Switzerland
    J Clin Invest 120:1310-23. 2010
    ..Together with evidence for a chemosensitizing activity of obatoclax in vivo, our data provide a compelling rationale for clinical translation of this pharmacological approach into treatments for patients with refractory ALL...
  48. pmc Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche
    Janine T Erler
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cancer Cell 15:35-44. 2009
    ..CD11b+ cells and LOX also colocalize in biopsies of human metastases. Our findings demonstrate a critical role for LOX in premetastatic niche formation and support targeting LOX for the treatment and prevention of metastatic disease...
  49. ncbi RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
    Hong Yang
    Discovery Oncology, Hoffmann La Roche, Inc, Nutley, New Jersey, USA
    Cancer Res 70:5518-27. 2010
    ..There was no toxicity observed in any dose group in any of the in vivo models tested. Our findings offer evidence of the potent antitumor activity of RG7204 against melanomas harboring the mutant BRAF(V600E) gene...
  50. ncbi Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus
    Qian Zhang
    Genelux Corporation, San Diego Science Center, San Diego, California 92109, USA
    Cancer Res 67:10038-46. 2007
    ..These findings suggest that immune activation may combine with viral oncolysis to induce tumor eradication in this model, providing a novel perspective for the design of oncolytic viral therapies for human cancers...
  51. ncbi Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
    ..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation...
  52. ncbi Regulation of androgen receptor activity by tyrosine phosphorylation
    Zhiyong Guo
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Cancer Cell 10:309-19. 2006
    ....
  53. pmc Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer
    Joseph E Carpentino
    McKnight Brain Institute, University of Florida, Gainesville, Florida 32609, USA
    Cancer Res 69:8208-15. 2009
    ..These data link colitis and cancer identifying potential tumor-initiating cells from colitic patients, suggesting that sphere and/or xenograft formation will be useful to survey colitic patients at risk of developing cancer...
  54. pmc A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Mol Cancer Ther 8:310-4. 2009
    ..Direct tumor xenografts are a valid platform to test multicompartment therapeutic approaches in pancreatic cancer...
  55. pmc Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
    Nathan T Ihle
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 69:143-50. 2009
    ....
  56. pmc Thioaptamer conjugated liposomes for tumor vasculature targeting
    Aman P Mann
    Department of Nanomedicine, University of Texas Health Science Center at Houston, 1825 Hermann Pressler, Houston, Texas 77030, USA
    Oncotarget 2:298-304. 2011
    ....
  57. ncbi A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer
    Manuel Hidalgo
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Mol Cancer Ther 10:1311-6. 2011
    ..The data support the use of the personalized tumorgraft model as a powerful investigational platform for therapeutic decision making and to efficiently guide cancer treatment in the clinic...
  58. ncbi Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer
    Ivan S Donev
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
    Clin Cancer Res 17:2260-9. 2011
    ..The purpose of this study was to determine whether inhibition of PI3K, a downstream molecule of both EGFR and MET, could overcome HGF-mediated EGFR-TKI resistance in EGFR mutant lung cancer cells PC-9 and HCC827...
  59. pmc Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus
    Ianko D Iankov
    Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Mol Ther 20:1139-47. 2012
    ..These data suggest that potent immunomodulators of bacterial origin, such as H. pylori NAP, can enhance the antitumor effect of oncolytic viruses and support the feasibility and potential of a combined viroimmunotherapy approach...
  60. pmc Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene
    Zhao Chen
    Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 70:9827-36. 2010
    ..Taken together, our findings define a murine model that offers a reliable platform for the preclinical comparison of combinatorial treatment approaches for lung cancer characterized by ALK rearrangement...
  61. ncbi AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical
    Barry R Davies
    Cancer and Infection Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    Mol Cancer Ther 6:2209-19. 2007
    ..Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel...
  62. ncbi Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice
    Michelle A Blaskovich
    Drug Discovery Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Res 63:1270-9. 2003
    ..These results give strong support for pharmacologically targeting the JAK/STAT3 signaling pathway for anticancer drug discovery...
  63. pmc An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
    Birgit Schoeberl
    Merrimack Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    Cancer Res 70:2485-94. 2010
    ..Thus, these results suggest that targeting ErbB3 with MM-121 can be an effective therapeutic strategy for cancers with ligand-dependent activation of ErbB3...
  64. pmc Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy
    H Harada
    Department of Radiation Oncology and Image Applied Therapy, Kyoto University Graduate School of Medicine, Sakyo ku, Japan
    Br J Cancer 100:747-57. 2009
    ....
  65. pmc Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:1046-52. 2009
    ..Moreover, IKKbeta inhibitors enhanced bortezomib-induced cytotoxicity. Our studies therefore suggest that bortezomib-induced cytotoxicity cannot be fully attributed to inhibition of canonical NF-kappaB activity in MM cells...
  66. pmc Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation
    Indira Jutooru
    Department of Veterinary Physiology and Pharmacology, Texas A and M University, College Station, Texas 77843, USA
    J Biol Chem 285:25332-44. 2010
    ....
  67. pmc Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
    Cristian Bellodi
    University of Leicester, United Kingdom
    J Clin Invest 119:1109-23. 2009
    ..Together, these findings suggest that autophagy inhibitors may enhance the therapeutic effects of TKIs in the treatment of CML...
  68. ncbi Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products
    Ajaikumar B Kunnumakkara
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:3853-61. 2007
    ..018 versus control). Overall, our results suggest that curcumin potentiates the antitumor effects of gemcitabine in pancreatic cancer by suppressing proliferation, angiogenesis, NF-kappaB, and NF-kappaB-regulated gene products...
  69. pmc Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer
    Michael Graham Espey
    Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Free Radic Biol Med 50:1610-9. 2011
    ..These data support the testing of pharmacologic ascorbate in adjunctive treatments for cancers prone to high failure rates with conventional therapeutic regimens, such as pancreatic cancer...
  70. pmc Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
    Anthony C Faber
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 106:19503-8. 2009
    ..These data indicate simultaneous inhibition of PI3K-mTOR and MEK signaling is an effective strategy for treating EGFR mutant lung cancers, including those with acquired resistance to EGFR TKIs...
  71. ncbi Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy
    Martine L M Lamfers
    Department of Neurosurgery, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    Cancer Res 62:5736-42. 2002
    ..These results support further development of Ad5-Delta24RGD in combination with radiation therapy for treatment of these highly malignant tumors...
  72. ncbi Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity
    Dharmalingam Subramaniam
    Section of Digestive Diseases and Nutrition, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126, USA
    Cancer Res 68:1962-9. 2008
    ..Taken together, these data suggest that the novel curcumin-related compound EF24 is a potent antitumor agent that induces caspase-mediated apoptosis during mitosis and has significant therapeutic potential for gastrointestinal cancers...
  73. pmc Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells
    Yanyan Li
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
    Clin Cancer Res 16:2580-90. 2010
    ..In this study, we evaluated sulforaphane, a natural compound derived from broccoli/broccoli sprouts, for its efficacy to inhibit breast CSCs and its potential mechanism...
  74. pmc Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations
    Georgia Konstantinidou
    Division of Hematology and Oncology, Simmons Comprehensive Cancer Center, and Hamon Center for Therapeutic Oncology Research, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas TX 75390, USA
    Cancer Res 69:7644-52. 2009
    ..These findings may have general applicability in cancer therapy, because aberrant activation of PI3K occurs frequently in human cancer...
  75. ncbi Modeling of tumor growth and anticancer effects of combination therapy
    Gilbert Koch
    Department of Mathematics and Statistics, University of Konstanz, Germany
    J Pharmacokinet Pharmacodyn 36:179-97. 2009
    ..The unique feature of the presented approach is the ability to characterize the nature of combined drug interaction as well as to quantify the intensity of such interactions by assessing the time course of combined drug effect...
  76. ncbi Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma
    Jose A Karam
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Eur Urol 59:619-28. 2011
    ..Animal models are instrumental in understanding disease pathophysiology and mechanisms of therapy action and resistance in vivo...
  77. pmc Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer
    Christine L Hann
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Cancer Res 68:2321-8. 2008
    ..Taken together, these data have specific implications for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the testing of novel anticancer strategies in relevant preclinical models...
  78. ncbi An in vivo platform for translational drug development in pancreatic cancer
    Belen Rubio-Viqueira
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:4652-61. 2006
    ....
  79. pmc Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action
    Wei Wang
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, and Comprehensive Cancer Center, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL 35294, USA
    Cancer Lett 278:241-8. 2009
    ..The data presented here support further evaluation of the ginsenosides for pancreatic cancer therapy...
  80. pmc Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo
    Jieru Meng
    Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 5:e14124. 2010
    ..Our study suggests that the combination of AZD6244 and MK2206 has a significant synergistic effect on tumor growth in vitro and in vivo and leads to increased survival rates in mice bearing highly aggressive human lung tumors...
  81. ncbi FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1
    Dmitri Pchejetski
    Department of Surgery and Cancer, Imperial College London, London, United Kingdom
    Cancer Res 70:8651-61. 2010
    ..Our findings suggest that low, well-tolerated doses of FTY720 could offer significant improvement to the clinical treatment of prostate cancer...
  82. ncbi Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models
    Alberto Gabizon
    Experimental Oncology Laboratory, Shaare Zedek Medical Center, 11 Shmuel Bayit Street, 7th Floor, PO Box 3235, Jerusalem 91031, Israel
    Cancer Chemother Pharmacol 66:43-52. 2010
    ..Targeting liposomes to the FR has been proposed as a way to enhance the effects of liposome-based chemotherapy...
  83. pmc FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 16:3182-92. 2010
    ..Because of the absence of curative therapy for MCL, we explored FTY720 as a novel agent against MCL...
  84. ncbi Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital, Taiwan
    J Hepatol 52:88-95. 2010
    ..Previously we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. Here we report that combined treatment with sorafenib and bortezomib shows synergistic effects in HCC...
  85. ncbi Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model
    Achuthamangalam B Madhankumar
    Department of Neurosurgery H110, G M Leader Family Laboratory, Penn State University, College of Medicine, M S Hershey Medical Center, 500 University Drive, Hershey, PA 17033 0850, USA
    Mol Cancer Ther 8:648-54. 2009
    ..These data show that IL-13 targeted nanovesicles are a viable option for the treatment of brain tumors...
  86. pmc High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish
    Konstantin Stoletov
    Department of Pathology and Moores Cancer Center, University of California at San Diego, 9500 Gilman Drive, MC0612, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 104:17406-11. 2007
    ..Zebrafish could also provide a cost-effective means for the rapid development of therapeutic agents directed at blocking human cancer progression and tumor-induced angiogenesis...
  87. ncbi Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
    Tammie C Yeh
    Array BioPharma, Inc, Boulder, Colorado 80301, USA
    Clin Cancer Res 13:1576-83. 2007
    ..We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these studies has been to show the biological efficacy of ARRY-142886 (AZD6244) in enzymatic, cellular, and animal models...
  88. ncbi Blocking neuropilin-2 function inhibits tumor cell metastasis
    Maresa Caunt
    Tumor Biology and Angiogenesis, Genentech, Inc, South San Francisco, CA 94080, USA
    Cancer Cell 13:331-42. 2008
    ..Our results demonstrate that Nrp2, which was originally identified as an axon-guidance receptor, is an attractive target for modulating metastasis...
  89. pmc Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
    Florence I Raynaud
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
    Mol Cancer Ther 8:1725-38. 2009
    ..Together, these data support the development of GDC-0941 as a potent, orally bioavailable inhibitor of phosphatidylinositide 3-kinase. GDC-0941 has recently entered phase I clinical trials...
  90. ncbi Intraperitoneal therapy of ovarian cancer using an engineered measles virus
    Kah Whye Peng
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:4656-62. 2002
    ..Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer...
  91. pmc Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
    George N Naumov
    Children s Hospital, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, and Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Clin Cancer Res 15:3484-94. 2009
    ..EGFR TKI resistance is not completely understood and has been associated with certain EGFR and K-RAS mutations and MET amplification...
  92. ncbi Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma, Inc, Tsukuba, Ibaraki, Japan
    Cancer Sci 102:614-21. 2011
    ..The broad and potent antitumor activity presented in the present study is indicative of the therapeutic potential of YM155 in the clinical setting...
  93. ncbi CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells
    Claudia M Kowolik
    Divisions of Molecular Medicine, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, USA
    Cancer Res 66:10995-1004. 2006
    ..These data imply that modifications to the CAR can result in improved therapeutic potential of CD19-specific T cells expressing this second-generation CAR...
  94. pmc Therapeutic potential of AZD1480 for the treatment of human glioblastoma
    Braden C McFarland
    Department of Cell Biology, 1918 University Blvd, MCLM 313, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Mol Cancer Ther 10:2384-93. 2011
    ....
  95. ncbi Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell
    Xiaoli Zhang
    Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
    Int J Cancer 129:2502-11. 2011
    ..Our study provided the first evidence for antitumor angiogenesis activity of indirubin and the related molecular mechanism. Our investigations suggested that indirubin was a potential drug candidate for angiogenesis related diseases...
  96. pmc Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways
    Tingfang Yi
    Center for Cancer and Stem Cell Biology, Institute for Bioscience and Technology, Texas A and M University System Health Science Center, 2121 West Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:1789-96. 2008
    ..Overall, our results indicate that thymoquinone inhibits tumor angiogenesis and tumor growth and could be used as a potential drug candidate for cancer therapy...
  97. ncbi Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model
    Serk In Park
    The Program in Cancer Biology, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, TX 77030, USA
    Cancer Res 68:3323-33. 2008
    ..Therefore, we conclude that SFKs are promising therapeutic targets for treatment of human prostate cancer and that Src and Lyn activities affect different cellular functions required for prostate tumor growth and progression...
  98. pmc Choosing the right cell line for breast cancer research
    Deborah L Holliday
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK
    Breast Cancer Res 13:215. 2011
    ....
  99. ncbi YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer
    Kentaro Yamanaka
    Drug Discovery Research, Astellas Pharma Inc, 21 Miyukigaoka, Tsukuba, Ibaraki 305 8585, Japan
    Int J Oncol 39:569-75. 2011
    ..These results suggest that the survivin-suppressing activity of YM155 may offer a novel therapeutic option for patients with metastatic TNBC...
  100. ncbi Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells
    Kuen Feng Chen
    Department of Medical Research, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei
    Cancer Res 68:6698-707. 2008
    ..Targeting Akt signaling overcomes drug resistance to bortezomib in HCC cells, which provides a new approach for the combinational therapy of HCC...
  101. ncbi YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Anticancer Drugs 22:454-62. 2011
    ....

Research Grants78

  1. Effect of HIV-1 Vpr on Basic Cellular Functions (II)
    Richard Zhao; Fiscal Year: 2007
    ..abstract_text> ..
  2. Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias
    JOHN PAGEL; Fiscal Year: 2008
    ..abstract_text> ..
  3. RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONS
    Dietmar Siemann; Fiscal Year: 2001
    ..Ultimately we hope that these approaches can be reliably developed to an extent where the use of human tumor biopsy material may lead to radiotherapy treatments more tailored to the individual patient. ..
  4. Mechanisms of chemopreventive effect of resveratrol
    Zigang Dong; Fiscal Year: 2009
    ..Our long-term goal is to identify the molecular mechanism explaining the anti-tumor effect exhibited by resveratrol. Such knowledge will help in developing better chemopreventive agents with fewer side effects. ..
  5. Molecular basis of arsenic-induced cell transformation
    Zigang Dong; Fiscal Year: 2007
    ..Such knowledge will facilitate the design of more effective and specific strategies with fewer side effects for chemoprevention of arsenic-induced cancer. ..
  6. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2005
    ..abstract_text> ..
  7. Study on Ultraviolet-induced Signal Transduction
    Zigang Dong; Fiscal Year: 2010
    ..These preclinical studies are designed to lead to the development of new strategies for the chemoprevention of human skin cancers. ..
  8. Anticarcinogenic Mechanisms of Tea Constituents
    Zigang Dong; Fiscal Year: 2007
    ....
  9. INHIBITION OF CARCINOGENESIS BY TEA AND TEA CONSTITUENTS
    Zigang Dong; Fiscal Year: 2010
    ..abstract_text> ..
  10. Targeting of the Androgen Receptor in Prostate Cancer
    John Isaacs; Fiscal Year: 2005
    ..These peptide prodrugs will be designed so that they are substrates for the enzymatic activity of either Prostate Specific Antigen. ..
  11. Antifolate Resistance in Osteosarcoma
    Richard Gorlick; Fiscal Year: 2007
    ....
  12. MAb-based targeted chemotherapy of lung cancer
    Serengulam Govindan; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  13. COORDINATED REGULATION OF ANTIOXIDANT ENZYMES
    Michael Kelner; Fiscal Year: 2005
    ..abstract_text> ..
  14. Calcitonin in Prostate Growth and Neoplasia
    Girish Shah; Fiscal Year: 2008
    ..abstract_text> ..
  15. Minimal-disease radioimmunotherapy of colorectal cancer
    Serengulam Govindan; Fiscal Year: 2003
    ..Successful feasibility study will lead to extended preclinical therapy studies and the initiation of a clinical Phase I RAIT trial in a SBIR Phase II program. ..
  16. GRSA Proteins in the Diagnosis of Breast Cancer
    WILLIAM NORTH; Fiscal Year: 2002
    ..These methods could be applicable to all patients with breast cancer or suspected breast cancer. ..
  17. Nicotine/NNK Signaling in Human Lung Cancer Cells
    Xingming Deng; Fiscal Year: 2008
    ..abstract_text> ..
  18. Translational Studies of Fn14 in Brain Tumors
    Nhan Tran; Fiscal Year: 2007
    ..The results from these studies will profile the suitability and applicability of Fn 14 as a target for therapeutic intervention. ..
  19. E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION
    Srikumar Chellappan; Fiscal Year: 2007
    ..We will also attempt to identify and evaluate the anti-cancer properties of agents that can modulate these processes. ..
  20. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2008
    ..Continue to examine the mechanisms by which flavopiridol potentiates CPT-11 induced apoptosis, which should provide the opportunity to identify new biomarkers of response for these flavopiridol drug combinations. ..
  21. Regulation of androgen metabolism by the nuclear receptor CAR
    Wendong Huang; Fiscal Year: 2008
    ..Manipulation of CAR activity by small molecules may be a novel approach for prostate cancer prevention and therapy. [unreadable] [unreadable] [unreadable]..
  22. Role of ErbB/Stat3 in the establishment and progression of pancreatic cancer
    James Freeman; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  23. EXPERIMENTAL TRANSFORMATION OF HUMAN MELANOCYTES IN VIVO
    Meenhard Herlyn; Fiscal Year: 2008
    ..Our unique model allows a systematic dissection of the biological and molecular events leading to human melanoma formation. ..
  24. Predictive Markers of Glioblastoma Response to VEGF Trap
    John de Groot; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  25. A High-Throughput Screen to Identify Small Molecule Compounds That Augment
    Brent Passer; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  26. FDG PET-CT in Metastatic Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2010
    ..Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ..
  27. A Serum Marker for Aggressive Prostate Cancer
    Donna M Peehl; Fiscal Year: 2010
    ....
  28. EGFR/Radiation Response and Resistance Interactions
    Paul M Harari; Fiscal Year: 2010
    ..In this research proposal, we seek to increase the percentage of cancer patients who benefit from leading cancer drugs through the identification and disabling of specific tumor cell molecules that promote treatment resistance. ..
  29. Efficacy of 25-hydroxyvitamin D3 in colon cancer chemoprevention
    Rajendra G Mehta; Fiscal Year: 2010
    ..The studies will provide a rationale for using 25(OH)D3 for the prevention of colon carcinogenesis. ..
  30. Regulation of Differentiation Gene Expression by MyoD
    Asoke K Mal; Fiscal Year: 2010
    ..It is our expectation that completion of these AIMS will lead to novel therapies for muscle-related diseases. ..
  31. Lycopene Chemoprevention of Lung Cancer in Ferret
    Xiang Dong Wang; Fiscal Year: 2010
    ..In addition, the establishment of a lung carcinogenesis model in ferrets provides a valuable tool for both lung cancer and carotenoid research fields. ..
  32. PROHIBITIN GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION
    Srikumar Chellappan; Fiscal Year: 2009
    ..We expect that these experiments will help elucidate the molecular mechanisms involved in prohibitin-mediated growth control and tumor suppression. ..
  33. Redox-Active Agents for Pancreatic Cancer
    Robert Dorr; Fiscal Year: 2009
    ..The underlying clinical trial is underway and has already produced objective evidence of efficacy for this drug combination. ..
  34. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
    ..This work is anticipated to enhance our understanding of KS pathogenesis, provide opportunities for novel therapies for KS, and contribute to the understanding of vascular biology. ..
  35. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2009
    ..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
  36. Green Tea Targets COX-2/PGE2 and EFGR Pathways in NSCLC via Stimulating Annexin 1
    Qing Yi Lu; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  37. Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
    Gary K Schwartz; Fiscal Year: 2010
    ..Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule. ..
  38. Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection
    Andrea Cuconati; Fiscal Year: 2008
    ..At the end of the proposed project, the novel compound would be ready for large-scale Phase III clinical testing with hepatitis B patients. [unreadable] [unreadable] [unreadable]..
  39. Tea Polyphenols in Chemoprevention of Prostate Cancer
    SUSANNE MARGARETE HENNING; Fiscal Year: 2011
    ..The results will assist in designing dietary supplements for chemoprevention of early stages of prostate cancer or during watchful waiting. ..
  40. CELL DEATH INDUCED BY ANTICANCER AGENTS
    Alan Eastman; Fiscal Year: 2007
    ..The ultimate goal of this research program will be to define which pathway and effector a specific leukemia uses, and then prescribe effective drug combinations that will be individualized for that patient. ..
  41. Pathophysiology of Arginine-induced Pancreatitis in Mice
    Ashok Saluja; Fiscal Year: 2006
    ..Successful completion of these studies will provide an excellent model of pancreatitis for future studies dealing with therapeutic interventions. ..
  42. MENTORING FOR NEW CANCER THERAPEAUTICS
    Gary Schwartz; Fiscal Year: 2005
    ..This K24 award mechanism represents the essence of what we are proposing and for which support is needed. ..
  43. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2004
    ..3). To develop strategies for reconstituting tumor defense in mice deficient in GM-CSF, IL-3, and IFN-gamma. ..
  44. COMPOSITION, ACTIVITY AND DRUG INTERACTIONS OF ECHINACEA
    CYNTHIA WENNER; Fiscal Year: 2004
    ..By addressing these aims, Dr. Wenner will gain strong research skills in botanical medicine and the expertise necessary to significantly impact this field. ..
  45. ALCOHOL INTAKE AND RETINOID METABOLISM AND SIGNALING
    Xiang Dong Wang; Fiscal Year: 2004
    ....
  46. SURFACE BINDING AND ACTIVATION OF MMP9 IN TUMOR CELLS
    Rafael Fridman; Fiscal Year: 2003
    ..The results of these studies will address a new paradigm in the regulation of proMMP-9 activation and may provide novel and specific tools to inhibit MMP-9 activity in human tumors. ..
  47. EXPERIMENTAL RADIOTHERAPY--CARCINOGENESIS, AND PROTECTOR
    DAVID GRDINA; Fiscal Year: 2003
    ..abstract_text> ..
  48. Cell Survival Pathways and Inhibitors in Leukemia
    Alan Eastman; Fiscal Year: 2003
    ....
  49. Biologic Activity of Lycopene
    Xiang Dong Wang; Fiscal Year: 2002
    ..These studies will provide important information for the potential future use of lycopene as cancer preventive nutrient at different tissue sites and the knowledge of possible adverse effects with tobacco. ..
  50. Bioavailability of Tea Polyphenols in Prostate Cancer
    Susanne Henning; Fiscal Year: 2002
    ..ODC enzyme activity will be determined measuring the release of 14C CO2 from 14C ornithine. These studies will provide information important in designing studies to critically test the role of dietary supplementation in prostate cancer. ..
  51. TNT IMAGING TO MONITOR THE EFFICACY OF CANCER THERAPY
    Alan Epstein; Fiscal Year: 2002
    ..abstract_text> ..
  52. ABROGATION OF CELL CYCLE ARREST BY STAUROSPORINE ANALOGS
    Alan Eastman; Fiscal Year: 2001
    ..These experiments should identify a drug combination that can be tested for its selective targeting to p53-defective tumors in future clinical trials. ..
  53. GENE SPECIFIC MUTATIONS IN SKIN INDUCED BY PEROXYNITRITE
    Fredika Robertson; Fiscal Year: 2001
    ..The hypothesis driving this research is that NO and peroxynitrite are mutagenic, and could be important contributors to oxidative DNA damage and mutation in human epidermal keratinocytes at sites of inflammation. ..
  54. CONTROL OF DIFFERENTIATION IN COLON CARCINOMA
    Luzhe Sun; Fiscal Year: 2001
    ....
  55. Second International Melanoma Research Congress
    Meenhard Herlyn; Fiscal Year: 2004
    ..This second congress will strengthen the field and solidify the ties between the different research and clinical communities. ..
  56. Regulation of Bilirubin Metabolism by the Receptor CAR
    Wendong Huang; Fiscal Year: 2005
    ..The findings will elucidate the essential role of CAR in bilirubin metabolism and have significant implications for development of more potent drugs for the treatment of human jaundice and other related diseases. ..
  57. Flavopiridol as a Potential Therapy in Multiple Myeloma
    Keith Bible; Fiscal Year: 2005
    ..Results of proposed studies will improve understanding of the effects and mechanism(s) of action of flavopiridol in myeloma cells, thereby potentially contributing to the further clinical development of the drug. ..
  58. Flavopiridol Targets Transcription Factor/DNA Complexes
    Keith Bible; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  59. Phase I Trial of Safingol and Cisplatin
    Gary Schwartz; Fiscal Year: 2006
    ..conduct "proof of principle" biological assays to measure the degree of ceramide production and/or S1P inhibition, either of which may be predictive of clinical outcome or toxicity. ..
  60. Delayed Radioprotection by Thiols
    DAVID GRDINA; Fiscal Year: 2006
    ..Two, elevation in MnSOD level without a concomitant increase in enzymatic activity can result from nitration of MnSOD by peroxynitrite (ONOO-). ..
  61. Meeting on Inhaled Mineral Dusts/Nanoparticles
    Brooke Mossman; Fiscal Year: 2005
    ..This meeting will provide a forum for exchange of research ideas and collaborations that will advance the field of public health in understanding individual susceptibility to and mechanisms of particulate-induced lung diseases. ..
  62. Expression of Proapoptotic Genes for Cancer Therapy
    Bingliang Fang; Fiscal Year: 2006
    ..Success of the proposed studies will lead to new therapeutics for refractory metastatic disease. It will also provide insight into mechanisms of resistance to apoptosis induction in cancer cells. ..
  63. Gene Modified Cell Lines as Vaccine for Pancreas Cancer
    Daniel Laheru; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] ..
  64. Interactions of Black Cohosh with Cancer Therapy
    Sara Rockwell; Fiscal Year: 2005
    ..This project will assess these possibilities. The findings will show whether this herb is inactive and harmless, potentially dangerous to breast cancer patients, or of potential value in the treatment of this disease. ..
  65. Vitamin D5 in Prevention of Mammary Carcinogenesis
    Rajendra Mehta; Fiscal Year: 2006
    ..Whether prohibitin plays a role in cell transformation and chemopreventive efficacy in these cells? 3. How is 1alpha(OH)D5 metabolized in normal and neoplastic mammary epithelial cells and tissues? ..
  66. Monoclonal Antibodies Against T-Regulatory Cells
    Alan Epstein; Fiscal Year: 2005
    ..Along with LEC/NHS76, this new antibody/drug conjugate should be applicable to use in humans and may provide clinicians with a vital weapon in our relentless effort to treat cancer. ..
  67. Molecular Requirements for Recombinant Cytotoxins Efficacy
    Waldemar Debinski; Fiscal Year: 2010
    ..It is expected that the new information gathered will be invaluable in further molecular design of recombinant anti-cancer cytotoxins. ..
  68. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2005
    ..To characterize effects of human anti-EGFRvIII antibodies on EGFRvIII signaling. 4. To determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide. ..
  69. Cell Cycle G2/M Pathway Modulated by Viral Protein R
    Richard Zhao; Fiscal Year: 2006
    ..These proposed studies will provide a comprehensive framework for this new cell cycle control pathway and provide insights into fundamental aspects of this new G2/M surveillance system of eukaryotic cells. ..
  70. Tumor suppressor adenomatous polyposis coli and breast carcinogenesis
    Satya Narayan; Fiscal Year: 2007
    ....
  71. ACOUSTICALLY ACTIVATED MICELLAR DRUG DELIVERY
    Natalya Rapoport; Fiscal Year: 2001
    ....
  72. INTERACTION OF APC AND P53 IN COLORECTAL CARCINOGENESIS
    Satya Narayan; Fiscal Year: 2001
    ..Therefore, novel therapeutic strategies may emerge with respect to potential new targets for chemotherapeutic intervention in colon cancer. ..
  73. Enhancement of Ad-p53 Therapy with Intratumoral Taxane
    GEORGE YOO; Fiscal Year: 2004
    ..Favorable data from the proposed project will lead to the development of clinical trials using intratumoral and intra-wound injections of docetaxel and Ad-p53. ..
  74. Lipitor/Celebrex: effect on prostate cancer progression
    Xi Zheng; Fiscal Year: 2007
    ..This combination of drugs may significantly improve the management of prostate cancer. [unreadable] [unreadable] [unreadable]..
  75. Targeting GRP78/BIP As An Adjunct Therapy For EGFR-positive Breast Cancer
    Marina Backer; Fiscal Year: 2008
    ..We expect that this data establish feasibility of clinical development for EGF-SLiP. [unreadable] [unreadable] [unreadable]..
  76. TAILORING ANTICANCER THERAPY TO LOSS OF P53
    David Fisher; Fiscal Year: 2003
    ..abstract_text> ..
  77. Mitf-Signal Responsive Transcription in Osteoclasts
    David Fisher; Fiscal Year: 2009
    ..The second represents a systematic approach to the identification of transcriptional targets of Mitf/TFE3 using screens which couple their biochemical activities to the signaling pathways in which they reside. ..
  78. Targeted Delivery of Anthrax Inhibitors
    Marina Backer; Fiscal Year: 2007
    ..In Phase II we will develop LFn-liposomes with combination of LF and EF inhibitors, validate these liposomes in animal models of anthrax infection, and pre-clinical steps required for IND filing. [unreadable] [unreadable] [unreadable]..